Clinical and demographic data, encompassing age, tumor grade at diagnosis (ISUP Grade Group), initial management of prostate cancer, time from diagnosis to BCR, serum PSA prior to PET/CT, PSA DT calculated through the three most recent PSA values prior to 18F-FACBC PET/CT and dichotomized as < or >6 months, were recorded for all the enrolled subjects and are summarized in Table 1. The gene discussed is BCR; the disease is prostate carcinoma.